AU2018370828B2 - Promoting trained immunity with therapeutic nanobiologic compositions - Google Patents

Promoting trained immunity with therapeutic nanobiologic compositions Download PDF

Info

Publication number
AU2018370828B2
AU2018370828B2 AU2018370828A AU2018370828A AU2018370828B2 AU 2018370828 B2 AU2018370828 B2 AU 2018370828B2 AU 2018370828 A AU2018370828 A AU 2018370828A AU 2018370828 A AU2018370828 A AU 2018370828A AU 2018370828 B2 AU2018370828 B2 AU 2018370828B2
Authority
AU
Australia
Prior art keywords
nanobiologic
composition
nanobiologic composition
drug
glycero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018370828A
Other languages
English (en)
Other versions
AU2018370828A1 (en
Inventor
Zahi Fayad
Leo JOOSTEN
Willem Mulder
Mihai NETEA
Jordi OCHANDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radboud Universiteit Nijmegen
Icahn School of Medicine at Mount Sinai
Original Assignee
Stichting Katholieke Universiteit
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Katholieke Universiteit, Icahn School of Medicine at Mount Sinai filed Critical Stichting Katholieke Universiteit
Publication of AU2018370828A1 publication Critical patent/AU2018370828A1/en
Application granted granted Critical
Publication of AU2018370828B2 publication Critical patent/AU2018370828B2/en
Priority to AU2025201252A priority Critical patent/AU2025201252A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018370828A 2017-11-21 2018-11-20 Promoting trained immunity with therapeutic nanobiologic compositions Active AU2018370828B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201252A AU2025201252A1 (en) 2017-11-21 2025-02-21 Promoting trained immunity with therapeutic nanobiologic compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589054P 2017-11-21 2017-11-21
US62/589,054 2017-11-21
PCT/US2018/061935 WO2019103998A2 (en) 2017-11-21 2018-11-20 Promoting trained immunity with therapeutic nanobiologic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201252A Division AU2025201252A1 (en) 2017-11-21 2025-02-21 Promoting trained immunity with therapeutic nanobiologic compositions

Publications (2)

Publication Number Publication Date
AU2018370828A1 AU2018370828A1 (en) 2020-06-04
AU2018370828B2 true AU2018370828B2 (en) 2024-11-21

Family

ID=66630773

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018370828A Active AU2018370828B2 (en) 2017-11-21 2018-11-20 Promoting trained immunity with therapeutic nanobiologic compositions
AU2025201252A Pending AU2025201252A1 (en) 2017-11-21 2025-02-21 Promoting trained immunity with therapeutic nanobiologic compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201252A Pending AU2025201252A1 (en) 2017-11-21 2025-02-21 Promoting trained immunity with therapeutic nanobiologic compositions

Country Status (7)

Country Link
US (4) US20200253884A1 (https=)
EP (1) EP3713548A4 (https=)
JP (3) JP7330994B2 (https=)
CN (1) CN111971028A (https=)
AU (2) AU2018370828B2 (https=)
CA (1) CA3082830A1 (https=)
WO (1) WO2019103998A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109640959B (zh) 2016-04-29 2023-03-17 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
WO2021263188A1 (en) * 2020-06-25 2021-12-30 Icahn School Of Medicine At Mount Sinai Live cell engagement assay
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CA3222851A1 (en) 2021-06-22 2022-12-29 Roy VAN DER MEEL Nucleic acid containing nanoparticles
JP2025511149A (ja) * 2022-03-31 2025-04-15 アイカーン スクール オブ メディスン アット マウント サイナイ 免疫調節のためのスフィンゴ脂質をロードしたナノ生物製剤
CA3258109A1 (en) 2022-06-03 2023-12-07 Bio-Trip B.V. LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045161A1 (en) * 2009-10-09 2013-02-21 Signablok, Inc. Methods and compositions for targeted imaging
WO2016154544A1 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2017024312A1 (en) * 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101096386A (zh) * 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
EP2217221B1 (en) * 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
CN105903029A (zh) * 2007-12-12 2016-08-31 大学健康网络 高密度脂蛋白样肽磷脂支架（“hpps”）纳米颗粒
EP2620156B1 (en) * 2010-08-23 2019-03-27 Kang Stem Biotech Co., Ltd. Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
US10995140B2 (en) * 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045161A1 (en) * 2009-10-09 2013-02-21 Signablok, Inc. Methods and compositions for targeted imaging
WO2016154544A1 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2017024312A1 (en) * 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MEGIAS ET AL.: "TLR2, TLR4 and Dectin-1 signalling in hematopoietic stem and progenitor cells determines the antifungal phenotype of the macrophages they produce", MICROBES AND INFECTION, vol. 18, no. 5, 2016, pages 354 - 363, XP055633353 *
NETEA ET AL.: "Trained immunity: A program of innate immune memory in health and disease", SCIENCE, vol. 352, no. 6284, 22 April 2016 (2016-04-22), pages aaf1098, XP055612144, DOI: 10.1126/science.aaf1098 *
NETEA MIHAI ET AL : "Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 102, no. 6, 10 October 2017 (2017-10-10), pages 1323 - 1332, DOI: 10.1189/jlb.5RI0217-064RR *
S.-C. CHENG ET AL: "mTOR- and HIF-1 -mediated aerobic glycolysis as metabolic basis for trained immunity", SCIENCE, vol. 345, no. 6204, 25 September 2014 (2014-09-25), US, pages 1250684 - 1250684, DOI: 10.1126/science.1250684 *

Also Published As

Publication number Publication date
EP3713548A2 (en) 2020-09-30
AU2025201252A1 (en) 2025-03-13
US20200261591A1 (en) 2020-08-20
JP2026015394A (ja) 2026-01-29
JP2023145781A (ja) 2023-10-11
WO2019103998A2 (en) 2019-05-31
WO2019103998A3 (en) 2019-08-22
AU2018370828A1 (en) 2020-06-04
US20200253884A1 (en) 2020-08-13
CA3082830A1 (en) 2019-05-31
EP3713548A4 (en) 2021-06-23
CN111971028A (zh) 2020-11-20
JP7772748B2 (ja) 2025-11-18
JP7330994B2 (ja) 2023-08-22
US20230355537A1 (en) 2023-11-09
US20250268839A1 (en) 2025-08-28
JP2021504446A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
US20250268839A1 (en) Promoting trained immunity with therapeutic nanobiologic compositions
EP2671086B1 (en) System and method for diagnosis and treatment
US10973822B2 (en) Combination therapy for treatment of hematological cancers and solid tumors
AU2011308504B2 (en) Therapeutic use of a TLR agonist and combination therapy
JP2024038199A (ja) 細菌由来ミニ細胞を含む組成物およびそれを使用する方法
WO2021086830A1 (en) Use of biomarkers to predict clinical sensitivity to 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
WO2021086829A1 (en) Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapies
CA3142952A1 (en) Pdl1 positive nk cell cancer treatment
EP3536334A1 (en) Cancer stem cell targeted cancer vaccines
JP2022516347A (ja) 腫瘍性疾患の治療のためのカプセル化グリコリピド抗原
AU2023308195A1 (en) Combination therapies of wdr5 inhibitors and pd-1 inhibitors
WO2020247830A1 (en) Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors
US20250222102A1 (en) Nk cells expressing il-15 and checkpoint inhibitors for the treatment of cancer
HK40106589A (en) Cancer stem cell targeted cancer vaccines
HK40059978A (en) Cancer stem cell targeted cancer vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)